Cited 2 times in
On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 김건민 | - |
dc.contributor.author | 김민환 | - |
dc.contributor.author | 김승일 | - |
dc.contributor.author | 김지예 | - |
dc.contributor.author | 김지형 | - |
dc.contributor.author | 박병우 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 박형석 | - |
dc.contributor.author | 손주혁 | - |
dc.contributor.author | 정준 | - |
dc.contributor.author | 조영업 | - |
dc.contributor.author | 김창곤 | - |
dc.contributor.author | 김슬기 | - |
dc.date.accessioned | 2023-04-20T08:29:38Z | - |
dc.date.available | 2023-04-20T08:29:38Z | - |
dc.date.issued | 2023-01 | - |
dc.identifier.issn | 1465-5411 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/194109 | - |
dc.description.abstract | Background Cyclin-dependent kinase 4 and 6 (CDK4/6) inhibitors have been established as a standard treatment for hormone receptor (HR)-positive, human epidermal growth factor receptor 2 (HER2)-negative advanced breast cancer (ABC); however, predictive biomarkers with translational relevance have not yet been elucidated. Methods Data from postmenopausal women who received the CDK4/6 inhibitor palbociclib and letrozole for HR-positive, HER2-negative ABC from tertiary referral centers were analyzed (N = 221; exploratory cohort). Pre- and on-treatment neutrophil-to-lymphocyte ratio (NLR) and derived NLR (dNLR; neutrophil/[leukocyte-neutrophil]) were correlated with survival outcomes. Data from the PALOMA-2 (NCT01740427) and PALOMA-3 studies (NCT01942135) involving patients treated with endocrine treatment with or without palbociclib were also analyzed (validation cohort). Prospectively enrolled patients (N = 20) were subjected to immunophenotyping with circulating immune cells to explore the biological implications of immune cell dynamics. Results In the exploratory cohort, palbociclib administration significantly reduced leukocyte, neutrophil, and lymphocyte counts on day 1 of cycle 2. Although the baseline dNLR was not significantly associated with progression-free survival (PFS), higher on-treatment dNLRs were associated with worse PFS (hazard ratio = 3.337, P < 0.001). In the PALOMA-2 validation cohort, higher on-treatment dNLRs were associated with inferior PFS in patients treated with palbociclib and letrozole (hazard ratio = 1.498, P = 0.009), and reduction in the dNLR after treatment was predictive of a survival benefit (hazard ratio = 1.555, P = 0.026). On-treatment dNLRs were also predictive of PFS following palbociclib and fulvestrant treatment in the PALOMA-3 validation cohort. Using flow cytometry analysis, we found that the CDK4/6 inhibitor prevented T cell exhaustion and diminished myeloid-derived suppressor cell frequency. Conclusions On-treatment dNLR significantly predicted PFS in patients with HR-positive, HER2-negative ABC receiving palbociclib and endocrine treatment. Additionally, we observed putative systemic immune responses elicited by palbociclib, suggesting immunologic changes upon CDK4/6 inhibitor treatment. | - |
dc.description.statementOfResponsibility | open | - |
dc.format | application/pdf | - |
dc.language | English | - |
dc.publisher | BioMed Central Ltd | - |
dc.relation.isPartOf | BREAST CANCER RESEARCH | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.subject.MESH | Antineoplastic Combined Chemotherapy Protocols / adverse effects | - |
dc.subject.MESH | Breast Neoplasms* / metabolism | - |
dc.subject.MESH | Female | - |
dc.subject.MESH | Humans | - |
dc.subject.MESH | Letrozole / therapeutic use | - |
dc.subject.MESH | Lymphocytes / metabolism | - |
dc.subject.MESH | Neutrophils / metabolism | - |
dc.subject.MESH | Receptor, ErbB-2 / metabolism | - |
dc.subject.MESH | Retrospective Studies | - |
dc.title | On-treatment derived neutrophil-to-lymphocyte ratio and survival with palbociclib and endocrine treatment: analysis of a multicenter retrospective cohort and the PALOMA-2/3 study with immune correlates | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학교실) | - |
dc.contributor.googleauthor | Chang Gon Kim | - |
dc.contributor.googleauthor | Min Hwan Kim | - |
dc.contributor.googleauthor | Jee Hung Kim | - |
dc.contributor.googleauthor | Seul-Gi Kim | - |
dc.contributor.googleauthor | Gun Min Kim | - |
dc.contributor.googleauthor | Tae Yeong Kim | - |
dc.contributor.googleauthor | Won-Ji Ryu | - |
dc.contributor.googleauthor | Jee Ye Kim | - |
dc.contributor.googleauthor | Hyung Seok Park | - |
dc.contributor.googleauthor | Seho Park | - |
dc.contributor.googleauthor | Young Up Cho | - |
dc.contributor.googleauthor | Byeong Woo Park | - |
dc.contributor.googleauthor | Seung Il Kim | - |
dc.contributor.googleauthor | Joon Jeong | - |
dc.contributor.googleauthor | Joohyuk Sohn | - |
dc.identifier.doi | 10.1186/s13058-022-01601-4 | - |
dc.contributor.localId | A00287 | - |
dc.contributor.localId | A00482 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A00984 | - |
dc.contributor.localId | A00999 | - |
dc.contributor.localId | A01475 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A01753 | - |
dc.contributor.localId | A01995 | - |
dc.contributor.localId | A03727 | - |
dc.contributor.localId | A05420 | - |
dc.relation.journalcode | J00402 | - |
dc.identifier.eissn | 1465-542X | - |
dc.identifier.pmid | 36635767 | - |
dc.subject.keyword | Advanced breast cancer | - |
dc.subject.keyword | CDK4/6 inhibitor | - |
dc.subject.keyword | Neutrophil-to-lymphocyte ratio | - |
dc.subject.keyword | Palbociclib | - |
dc.contributor.alternativeName | Kim, Gun Min | - |
dc.contributor.affiliatedAuthor | 김건민 | - |
dc.contributor.affiliatedAuthor | 김민환 | - |
dc.contributor.affiliatedAuthor | 김승일 | - |
dc.contributor.affiliatedAuthor | 김지예 | - |
dc.contributor.affiliatedAuthor | 김지형 | - |
dc.contributor.affiliatedAuthor | 박병우 | - |
dc.contributor.affiliatedAuthor | 박세호 | - |
dc.contributor.affiliatedAuthor | 박형석 | - |
dc.contributor.affiliatedAuthor | 손주혁 | - |
dc.contributor.affiliatedAuthor | 정준 | - |
dc.contributor.affiliatedAuthor | 조영업 | - |
dc.citation.volume | 25 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 4 | - |
dc.identifier.bibliographicCitation | BREAST CANCER RESEARCH, Vol.25(1) : 4, 2023-01 | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.